Drug Profile
RPR 115781
Alternative Names: RPR115781Latest Information Update: 06 Dec 2002
Price :
$50
*
At a glance
- Originator Aventis
- Developer Nonindustrial source
- Class Antineoplastics; Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Nov 2000 Preclinical development for Cancer in France (Unknown route)